The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
A study showed that the triplet therapy isatuximab, pomalidomide, and dexamethasone (IsaPd) is an option for daratumumab-refractory multiple myeloma (MM), though the “modest”
By: Phillip McLeod The European Commission (EC) has approved blinatumomab (Blincyto) as a consolidation therapy for adult patients newly diagnosed with Philadelphia chromosome-negative,
In a video interview during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, Sagar Lonial, MD,
Haploidentical transplantation combined with unrelated cord blood resulted in superior one-year disease-free survival compared with the same transplant using bone marrow in patients
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of lisocabtagene maraleucel (lise-cel) for
After a median follow-up of 42.5 months, zanubrutinib resulted in a sustained progression-free survival (PFS) benefit compared with ibrutinib, with responses deepening over
The US Food and Drug Administration (FDA) granted Orphan Drug designation to MB-105, a CD5-targeted chimeric antigen receptor (CAR)-T cell therapy, for the
Differences in the bone marrow microenvironment may determine why some relapsed acute myeloid leukemia (AML) patients respond better to donor lymphocyte infusion (DLI)
A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume
Results of the CARTITUDE-4 trial assessing patient-reported outcomes in those with multiple myeloma receiving the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel
